Organon Stock (NYSE:OGN), Trade Ideas

Organon

Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Earnings

News

Federal Reserve

Markets

Trading Ideas

The S&amp;P 500 notched a marvelous rally in the first three months of 2024, banking on AI optimism and hopes that the Federal Reserve will cut interest rates in the second half of this year.

Play Safe! S&amp;P 500 is Teasingly Close to its 50 DMA: 3 Picks

Small Cap

ETFs

CRGY

USHY

WFHY

Launched on 04/27/2016, the WisdomTree U.S. High Yield Corporate Bond ETF (BATS: WFHY) is a smart beta exchange traded fund offering broad exposure to the High-Yield/Junk Bond ETFs category of the market.

What Are Smart Beta ETFs?

Is WisdomTree U.S. High Yield Corporate Bond ETF (WFHY) a Strong ETF Right Now?

Dividends

Health Care

Price Target

Pre-Market Outlook

Analyst Ratings

General

AMGN

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a  high dividend payout. 

Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Health Care Stocks Delivering High-Dividend Yields

Organon & Co

Origin Protocol - United States Dollar

OROGEN ROYALTIES INC by Orogen Royalties Inc.

Orogen Royalties Inc

ORGANA TECHS GRP INC by Organa Technologies Group, Inc.

Scotiabank analyst Konark Gupta maintains Canadian Pacific Kansas (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CP#TSX">CP</a>) with a Sector Perform and lowers the price target from C$126 to C$124.

TSX:CP

Scotiabank Maintains Sector Perform on Canadian Pacific Kansas, Lowers Price Target to C$124

Stephens &amp; Co. analyst Justin Long maintains Westinghouse Air Brake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) with a Overweight and raises the price target from $165 to $180.

Stephens & Co. Maintains Overweight on Westinghouse Air Brake, Raises Price Target to $180

Raymond James analyst Matt Roberts reiterates Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) with a Outperform and raises the price target from $225 to $240.

Reiteration

Raymond James Reiterates Outperform on Avery Dennison, Raises Price Target to $240

Chinese electric vehicle (EV) manufacturer&nbsp;XPeng&nbsp;Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) is reportedly considering overseas production amid an ongoing European investigation into&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/04/38288608/why-xpeng-shares-are-rising-today" rel="noreferrer noopener">Chinese-made EVs and regulatory adjustments.</a>
The European Commission initiated an investigation&nbsp;in October,&nbsp;questioning whether Chinese-made EVs, bolstered by state subsidies, gain an unfair advantage.
China has criticized the probe as protectionist. Brian Gu, co-president of&nbsp;Volkswagen&nbsp;AG&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>)-backed XPeng, mentioned during the Beijing auto show that the company currently exports limited&nbsp;quantities of&nbsp;EVs, reported Reuters.
However, evolving regulatory landscapes in the European Union might necessitate a strategic review.
While XPeng&nbsp;eyes&nbsp;a significant uptick in international sales, currently comprising 1%-2% of total sales, this figure could soar to approximately 10% this year, as per the report.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/04/38424183/tesla-is-betting-big-on-robotaxi-but-this-rival-thinks-elon-musks-vision-could-be-more-than-5-years" rel="noreferrer noopener">Tesla Is Betting Big On Robotaxi, But This Rival Thinks Elon Musk&#8217;s Vision Could Be &#8216;More Than 5 Years Away&#8217;</a>
Notably,&nbsp;the company aims to penetrate the U.S. market, albeit challenges hinder definitive entry plans.
Amid scrutiny of Chinese EV exports by Europe and the U.S., XPeng emphasized the importance of supporting the global transition to green technology.
Despite hurdles, the company eyes expansion into European markets such as France, Italy, and the U.K., bolstering its existing presence in the Netherlands, Norway, and Germany.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/04/38386240/automotive-industry-shifts-gears-electric-cars-to-dominate-roads-by-2030" rel="noreferrer noopener">Automotive Industry Shifts Gears: Electric Cars To Dominate Roads By 2030</a>
Price Action: XPEV shares are trading lower by 0.85% at $7.02 at last check Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image by Robert Way via Shutterstock

Equities

Media

VWAGY

XPEV

XPeng Fears Tariff Hike In Europe, Reportedly Considers Investing Abroad

WIIM

AMSF

AMERISAFE shares are trading lower after the company reported Q1 financial results.

Scotiabank analyst George Farmer maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Sector Perform and raises the price target from $83 to $85.

BMRN

Scotiabank Maintains Sector Perform on Biomarin Pharmaceutical, Raises Price Target to $85

WNS shares are trading lower after the company issued FY25 guidance with a midpoint below estimates.

In a tumultuous day for tech stocks, the collective market value of the Magnificent 7 tech giants plummeted by over $300 billion in the first trading hour on Thursday, primarily fueled by a weaker-than-expected revenue outlook from Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and concerning economic indicators arising from the first-quarter<a href="https://www.benzinga.com/economics/macro-economic-events/24/04/38429782/us-economy-grows-1-6-in-q1-slightly-below-expectations-as-price-pressures-weigh-o"> gross domestic product release.</a>
What Happened: Meta Platforms outperformed Wall Street's expectations with first-quarter revenue of $36.45 billion, a 27% increase year-over-year, and earnings per share of $4.71, beating the predicted $4.32. Investors pulled back after the social media giant issued subdued guidance <a href="https://www.benzinga.com/news/earnings/24/04/38416273/meta-platforms-q1-earnings-highlights-facebook-owner-beats-estimates-but-guidance-higher-costs-ding">for the upcoming quarter.</a> 
The company&#8217;s forecast for the second quarter anticipates revenue between $36.5 billion and $39 billion, putting the lower end of the range below the consensus estimate of $38.3 billion. 
Additionally, the social media giant anticipates increases in infrastructure and legal costs — pushing full-year expenses to between $96 billion and $99 billion. 
Compounding the tech sector&#8217;s woes were the latest GDP figures released Thursday by the Bureau of Labor Statistics. 
The U.S. economy expanded at a significantly reduced pace of 1.6% on an annualized basis in the first quarter of 2024, a sharp deceleration from the previous quarter&#8217;s 3.4% growth rate and well below the forecasted 2.5%.
Inflation concerns were reignited with the Personal Consumption Expenditure (PCE) price indices for the first quarter showing an increase. 
The headline PCE price index accelerated from 1.8% in the previous quarter to 3.4% , while the core PCE price index, which excludes food and energy prices and is a key inflation measure for the Federal Reserve, climbed from 2% to 3.7%, surpassing expectations of 3.4%.
Read also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38434513/us-growth-slows-in-q1-yet-inflation-acceleration-signals-stagflation-the-worst-poss">US Growth Slows In Q1, Yet Inflation Acceleration Signals Stagflation: &#8216;The Worst Possible Outcome For The Fed&#8217;</a>
<h3 class="wp-block-heading">Mag7 Stocks, Bond Market React</h3>
The Magnificent Seven had cumulatively wiped out $303 billion of market value by 11 a.m. in New York. 
Meta suffered the heaviest losses, down 13%, shedding $143 billion alone. Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) also sharply contributed to the tech market rout, wiping out $126 billion, down 4.3% ahead of the company&#8217;s earnings report after the market close. 
Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) both witnessed similar declines, while Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) managed to avoid losses. 
NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) saw some gains, outperforming the basket.
The Roundhill Magnificent Seven ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NYSE">MAGS</a>) fell 3%. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Market Cap</th>
<th>Market Cap Loss/Gain (1-day)</th>
<th>1-Day % Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microsoft Corporation</td>
<td>$2,905.08B</td>
<td>-$128.47B</td>
<td>-4.37%</td>
</tr>
<tr>
<td>Apple Inc.</td>
<td>$2,602.88B</td>
<td>-$7.08B</td>
<td>-0.27%</td>
</tr>
<tr>
<td>NVIDIA Corporation</td>
<td>$2,018.70B</td>
<td>+$59.39B</td>
<td>+2.94%</td>
</tr>
<tr>
<td>Alphabet Inc.</td>
<td>$1,933.75B</td>
<td>-$54.09B</td>
<td>-2.76%</td>
</tr>
<tr>
<td>Amazon.com, Inc.</td>
<td>$1,783.97B</td>
<td>-$51.15B</td>
<td>-2.81%</td>
</tr>
<tr>
<td>Meta Platforms, Inc.</td>
<td>$1,101.35B</td>
<td>-$132.35B</td>
<td>-13.17%</td>
</tr>
<tr>
<td>Tesla, Inc.</td>
<td>$528.24B</td>
<td>+$11.44B</td>
<td>+1.60%</td>
</tr>
<tr>
<td>Total</td>
<td>$12,873.97B</td>
<td>-$302.91B</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 11:00 a.m. ET. </figcaption></figure>
Treasury yields, particularly the two-year note, surged past 5%, reflecting heightened investor anxiety over inflation and its potential implications for future Federal Reserve actions. 
This resulted in a broad sell-off in bonds, with significant losses noted in long-term treasury ETFs such as the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>), which declined 0.8%.
The broader stock market also felt the pinch, with major indices recording significant losses. 
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and the tech-heavy Nasdaq 100 index, as tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), fell by 1.4% and 1.7%, respectively. 
Notably, the communication services sector was among the hardest hit, with the Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) plunging 4.4%, marking its worst session since October 2022.
Read now: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38415577/tesla-posts-strongest-session-since-january-2022-is-a-trend-reversal-underway">Tesla Posts Strongest Session Since January 2022: Is A Trend Reversal Underway?</a>
Photo via Shutterstock.

Large Cap

Macro Economic Events

Macro Notification

Market Summary

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Treasuries

Econ #s

Economics

Intraday Update

Tech

AAPL

AMZN

GOOGL

MAGS

MSFT

NVDA

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

Magnificent 7 Tumble, Wipe Out $300 Billion On Meta's Weak Guidance, Q1 Stagflation Woes

Scotiabank analyst Andres Coello maintains America Movil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>) with a Sector Perform and raises the price target from $16.6 to $17.2.

Scotiabank Maintains Sector Perform on America Movil, Raises Price Target to $17.2

With the average one-bedroom, 600-square-foot New York City apartment renting for about $3,760 per month, rent prices have stretched affordability for the city's residents.
It's no wonder politicians have sought to make housing more affordable in the city, but a policy aimed at doing so has been blamed, in part, for the struggles of New York Community Bancorp Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYCB#NYSE">NYCB</a>), which has seen its stock drop over 72% year to date.
NYCB has been hit with a double whammy. In 2019, a change in New York's law limited rent increases, which subsequently lowered profits for building owners. Combined with high interest rates, building debt and maintenance costs have soared without revenue growing at the same rate.
Don't Miss:
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
"This is going to end poorly for the city because we&#8217;re all on borrowed time and someone has to pay," StoneCastle Partners CEO Joshua Siegel said.
Despite a $1 billion cash infusion in March by a group of investors, including former U.S. Treasury Secretary Steven Mnuchin's firm, NYCB's share price is plummeting.
In an interview with CNBC, Mnuchin shared his belief that "a billion dollars into the balance sheet really strengthens the franchise" and that "whatever issues there are in the loans we'll be able to work through."
However, not everyone believes the billion-dollar capital infusion in the business will be enough.
Whalen Global Advisors Chairman Chris Whalen said $1 billion is far from enough.&nbsp;
Trending
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/go/grow-wealth-passively">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
</ul>
"We need 10," he said, adding that $1 billion is "chump change" in this situation.
Last March, NYCB bought the assets of Signature Bank, which was caught up in the 2023 regional banking crisis that took down Silicon Valley Bank.
Silicon Valley Bank was the second-largest bank collapse in U.S. history behind Washington Mutual's 2008 collapse.
In the span of a few days, its concentrated deposit base of tech startups with limited deposits insured by the Federal Deposit Insurance Corp. led to a fear-driven bank run, ultimately forcing the banks to shut down.
NYCB also has some concentration risk. According to The Real Deal, a real estate news provider, approximately 22% of NYCB's loan book is tied up in rent-controlled New York City buildings.
Yahoo Finance senior reporter David Hollerith writes that the scope of the problem is much worse. He said roughly half of NYCB's portfolio is tied to rent-controlled multifamily complexes in New York City.
Read Next:
<ul>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
<li>Whole Foods&#8217; Landlord Has Achieved A 15% Net IRR For Accredited Investors Since 2015 — <a href="https://www.benzinga.com/go/whole-foods-landlord">Discover The Latest Investment Opportunities On Its Platform</a>.</li>
</ul>

Real Estate

NYCB

NYC's Rent-Controlled Apartments Partly Behind NYCB Issues, Analysts Question If $1 Billion Lifeline Enough To Avoid SVB-Like Collapse

With the median single-family home in California selling for nearly $860,000 in 2023 — more than double the national median — prospective first-time homebuyers are having a tough time breaking into the state's expensive real estate market.
Mortgage rates topping 7%, combined with persistent inflation pushing off expected Federal Reserve rate cuts, make affordability even more challenging.&nbsp;
California allocated $250 million to relaunch its Dream for All program, which seeks to make housing more equitable for first-time homebuyers.
Don't Miss:
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
Dream for All is run by the California Housing Finance Agency, with the agency using a lottery system to give between 1,700 and 2,000 prospective first-time buyers up to $150,000 to purchase homes.
The catch is that the money is a loan that must be paid back along with a share of the home's price appreciation when it's sold if there is any.
"When they repay this, this is going back into the program, and it&#8217;s going to allow someone else to take advantage," California real estate agent Sarah Moore said.
In addition to homebuyers being potential beneficiaries of the program, it could also provide a runway for homebuilders who need to keep adding supply to fill the nation's demand for affordable housing units.
Trending
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/go/grow-wealth-passively">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
</ul>
Homebuilders such as Lennar Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) and D.R. Horton Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) have seen their shares soar around 52% and 54%, respectively, over the past year as the nation deals with a housing shortage.
While the Dream for All program provides loans, it comes at a time when California continues to run a massive budget deficit.
The nonpartisan Legislative Analyst's Office in February updated its estimate of California's deficit to as high as $73 billion.
Whether the government's intervention in an unaffordable housing market for most prospective first-time homebuyers in California proves effective in the long term remains to be seen, but for the winners of the lottery, it might end up being their only choice to afford to own property in the high-cost state.
Read Next:
<ul>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
<li>Whole Foods&#8217; Landlord Has Achieved A 15% Net IRR For Accredited Investors Since 2015 — <a href="https://www.benzinga.com/go/whole-foods-landlord">Discover The Latest Investment Opportunities On Its Platform</a>.</li>
</ul>

California's $250 Million 'Dream For All' Program Shells Out $150K In First-Time Homebuyer Funds Despite State's $73 Billion Deficit

Computershare Limited (ASX: CPU) has announced that it has agreed to acquire BNY Trust Company of Canada from BNY Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) through its Canadian trust company, Computershare Trust Company of Canada.
BNY Trust Company of Canada was established in 2001 and offers a range of trust and agency services in Canada to clients, including issuers, corporations, banks and government entities.
"We're delighted to be bringing the experienced team at BNY Trust Company of Canada on board," said Frank Madonna, CEO of Computershare Corporate Trust.
"The acquisition is squarely in line with our core strategy of building the scale and capability of our corporate trust operation and demonstrates our commitment to the provision of corporate trust services in North America."
"Computershare is the right choice for BNY Trust Company of Canada, and we are confident in their ability to ensure our clients continue to receive best-in-class service. In turn, we remain fully focused and committed to our global Corporate Trust franchise outside Canada," said Cécile Nagel, Global Head of Corporate Trust, BNY Mellon.
"We've invested heavily in our corporate trust business in recent years, including the acquisition and integration of the business from Wells Fargo, and we're well placed to provide continuity of services through our highly experienced teams and market-leading operations," said Toni De Luca, Head of Corporate Trust – Canada at Computershare.
BNY Trust Company of Canada is based in Toronto and has a portfolio of around 1,800 corporate trust mandates.
Computershare said it expected all relevant staff members to transfer as part of the deal, with new employees being able to operate from its own Toronto office.
The deal is scheduled to complete in the second half of calendar year 2024, subject to regulatory notifications and approvals and other customary closing conditions.
Computershare and BNY Mellon will work collaboratively to ensure the smooth transition of the business and staff.

Asset Sales

Computershare Limited Has Announced That It Has Agreed To Acquire BNY Trust Company Of Canada From BNY Mellon

RPC shares are trading lower after the company missed Q1 earnings and sales estimates.

Royal Caribbean Cruises Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) reported first-quarter 2024 revenue growth of $3.73 billion, a 29.2% year-over-year increase, <a href="https://www.benzinga.com/pressreleases/24/04/n38425099/royal-caribbean-group-reports-first-quarter-results-and-increases-full-year-guidance-on-continued-">beating the analyst consensus estimate of $3.7 billion</a>.
Passenger ticket revenues rose 34% Y/Y to $2.54 billion versus last year.
Total cruise operating expenses were $2.06 billion versus $1.79 billion a year ago.&nbsp;
Gross Cruise Costs per Available Passenger Cruise Days (APCD) increased 5.1%.
Gross margin yields increased 60.3% as-reported, and net yields increased 19.3% in constant currency versus first-quarter 2024.
Operating income for the quarter jumped 175% to $750 million, with an operating margin of 20.1%.
The occupancy rate in first-quarter was 107% versus 102.1% last year.
Royal Caribbean held $437 million in cash and equivalents as of March 31, 2024.
Adjusted EPS of $1.35 <a href="https://www.benzinga.com/calendars/earnings">beat the consensus</a> estimate of $1.33.
As of March 31, the group&#8217;s customer deposit balance was $6 billion.  
Royal Caribbean CEO Jason Liberty called it &#8220;a great start to the year,&#8221; citing growing demand for the company&#8217;s &#8220;outperformance in the first quarter, a further increase of full year earnings guidance, and 60% expected earnings growth year over year.&#8221;
Outlook: Royal Caribbean expects FY24 net yields to increase 9% to 10% in constant currency vs. 2023.
RCL raised its FY24<a href="https://www.benzinga.com/pressreleases/23/02/n30760190/royal-caribbean-group-reports-2022-results-and-provides-forward-guidance"> </a>adjusted EPS guidance <a href="https://www.benzinga.com/news/earnings/24/02/36891243/whats-going-on-with-royal-caribbean-cruises-stock-thursday">from $9.50 &#8211; $9.70 </a>to $10.70 &#8211; $10.90 against the consensus of $10.06.
The company sees second-quarter net yields to increase 10.20% to 10.70% in constant currency. RCL sees adjusted EPS of $2.65 &#8211; $2.75.
Price Action: RCL shares are trading higher by 1.56% at $138.70 at the last check Thursday.
Now Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38434513/us-growth-slows-in-q1-yet-inflation-acceleration-signals-stagflation-the-worst-poss">US Growth Slows In Q1, Yet Inflation Acceleration Signals Stagflation &#8211; &#8216;The Worst Possible Outcome For The Fed&#8217;</a>

Royal Caribbean Cruises Through Q1 As Demand And Pricing Remains High

$1.4 billion investment in Indiana plant brings production of an all-new&nbsp;BEV
Toyota adds up to 340 new, sustainable&nbsp;U.S. jobs
PRINCETON, Ind., April 25, 2024 /PRNewswire/ --&nbsp;Toyota will prepare for assembly of an all-new, three row battery electric SUV in the U.S. as part of a new $1.4 billion investment in its Princeton facility, affirming Toyota's commitment to reinvesting profits in its U.S. operations and bringing total investment in Toyota Indiana to $8 billion. This also brings the addition of up to 340 new, high-quality jobs with long-term stability.
&nbsp;
Toyota Charges Up Investment and Jobs in U.S. Manufacturing
&nbsp;
This investment will not only provide plant infrastructure to build the all-new BEV, it will add a new battery pack assembly line using lithium-ion batteries supplied by Toyota Battery Manufacturing North Carolina, a $13.9 billion facility slated to begin production in 2025.
&nbsp;
"Our team members are the heart of Toyota," said Tim Hollander, president of Toyota Indiana. "We take great pride in producing quality products while providing long-term, stable employment no matter the changes in our industry. Our team is committed to delivering this new product with the same quality and performance that Toyota customers expect."
Toyota's Indiana facility is home to more than 7,500 team members who assemble the Toyota Sienna, Highlander, Grand Highlander and the Lexus TX.
"I feel fortunate for the years I've been with Toyota and am proud of the products we assemble," said Michael Baehl, a 26-year Toyota Indiana team member. "The company's commitment to long-term job stability and high-quality work provides me with peace of mind. Additionally, the opportunities to enhance my skills and progress in my career have allowed me to achieve goals I never imagined."
Since 2021, Toyota has announced new investments totaling $18.6 billion into its U.S. manufacturing operations to support electrification efforts. Increasing BEV production in the U.S. advances Toyota's portfolio approach to electrification.
"Indiana and Toyota share a nearly 30-year partnership that has cultivated job stability and economic opportunity in Princeton and the surrounding southwest Indiana region for decades," said Governor Eric J. Holcomb. "Toyota's investment in the state began with an $800 million commitment and has grown to over $8 billion. Today's incredible announcement shows yet again just how important our state's business friendly environment, focus on long-term success and access to a skilled workforce is to companies seeking to expand and be profitable far into the future. Indiana proudly looks forward to continuing to being at the center of the future of mobility."&nbsp;
This announcement comes on the heels of a $1.3 billion investment in Toyota Kentucky for the production of a separate all-new, three row battery electric SUV.

Toyota Charges Up Investment And Jobs In U.S. Manufacturing, Investing $1.4B To Make New Electric SUV At Princeton Plant; Also Brings The Addition Of Up To 340 New, High-Quality Jobs With Long-Term Stability

UBS analyst Michael Lasser maintains WW International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) with a Neutral and lowers the price target from $3 to $2.1.

UBS Maintains Neutral on WW International, Lowers Price Target to $2.1

OPRA

Opera shares are trading lower following mixed Q1 results.

MicroCloud Hologram's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NYSE">HOLO</a>) short percent of float has risen 54.3% since its last report. The company recently reported that it has 753 thousand shares sold short, which is 19.18% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>MicroCloud Hologram Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714059025_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for MicroCloud Hologram has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing MicroCloud Hologram's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, MicroCloud Hologram's peer group average for short interest as a percentage of float is 2.82%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

Peering Into MicroCloud Hologram's Recent Short Interest

O-I Glass's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OI#NYSE">OI</a>) short percent of float has fallen 17.1% since its last report. The company recently reported that it has 4.36 million shares sold short, which is 4.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>O-I Glass Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714059020_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for O-I Glass has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing O-I Glass's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, O-I Glass's peer group average for short interest as a percentage of float is 2.39%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into O-I Glass's Recent Short Interest

Matterport's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTTR#NYSE">MTTR</a>) short percent of float has risen 24.31% since its last report. The company recently reported that it has 8.91 million shares sold short, which is 3.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.67 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Matterport Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714059014_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Matterport has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Matterport's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Matterport's peer group average for short interest as a percentage of float is 11.23%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MTTR

(MTTR) - Analyzing Matterport's Short Interest

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Some stocks glitter more prominently than others in the vast investment pool. However, amidst the popularity of high-profile names, a line of overlooked stocks exists, steadily leading to a market edge. 



Let&rsquo;s explore three overlooked stocks, each armed with a strategic edge, ready to capitalize on emerging trends. With its rapid top-line growth, even against macro adversity, the first holds stability and strategic potency. The second one is expanding rapidly with its growth acquisition strategy while maintaining its financial discipline and low-debt profile. Meanwhile, solid top-line growth and a diverse portfolio fueled the third one&rsquo;s steady uplift. This company defies industry challenges with unwavering determination.



Read more to learn the fundamental depths of these hidden treasures and the strategic vision that may build their market edge.



<h2>Heidrick &amp; Struggles (HSII)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/corporate-board-300x169.jpg" alt="A diverse group of adults sit at a high table in corporate attire."><div>Source: Shutterstock</div></div>Heidrick &amp; Struggles&rsquo; (NASDAQ:<a href="https://investorplace.com/stock-quotes/hsii-stock-quote/">HSII</a>) constant top-line growth and stability suggest the company&rsquo;s resilience and strategic mark in adverse market conditions. For instance, HSII delivered solid Q3 2023 <a href="https://investors.heidrick.com/static-files/67e57628-9b85-4938-93af-940c63dbc652">revenue of&nbsp;$263 million</a>, almost hitting a record high, reflecting its solid market position and client demand for its services. Furthermore, the top-line growth of 3% year over year (YOY) suggests a positive trend. Hence, this hints at the company&rsquo;s capacity to sustain and improve its performance over time.



Additionally, the stability of revenue is vital, despite the uncertain macro environment. Heidrick &amp; Struggles has sharply managed external adversities, such as geopolitical risks and market volatility, to maintain a steady income stream. Hence, this resilience represents the company&rsquo;s solid business model and operational edge. This enables it to counter external shocks and continue delivering value to its clients.



Furthermore,&nbsp;<a href="https://seekingalpha.com/article/4643579-heidrick-and-struggles-international-inc-hsii-q3-2023-earnings-call-transcript">strategic acquisitions</a>, such as Atreus and B4Z, contributed considerably to top-line growth. The effect is particularly felt in the On-Demand Talent and Heidrick Consulting segments. These acquisitions have expanded the company&rsquo;s geographic presence and market reach, as seen in the larger footprint in Europe post-Atreus acquisition. Fundamentally, strategic acquisitions enable HSII to access new verticals, technologies, and talent pools, boosting accelerated growth and a competitive edge.



Finally, the diversification strategy supports the company&rsquo;s top-line growth and stability. Specifically, the company diversified its services beyond executive search through a mix of diversified solutions, including On-Demand Talent, Heidrick Consulting, and Heidrick Digital. This extra revenue represents a barrier to the cyclicality in the traditional executive search business. Thus, diversified solutions now represent approximately <a href="https://seekingalpha.com/article/4643579-heidrick-and-struggles-international-inc-hsii-q3-2023-earnings-call-transcript">25% of overall company revenues</a>. Overall, this reduces the company&rsquo;s dependence on any single source of revenue and expands its valuation potential.



<h2>Evolution Petroleum (EPM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/clean-fuel-westport-wprt-1600-300x169.png" alt="wes stock image of fuel being poured into a vehicle fuel system"><div>Source: shutterstock.com/Me dia</div></div>Evolution Petroleum (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/epm-stock-quote/">EPM</a>) has capitalized on developed oil and gas fields based on secondary recovery techniques for additional value for years.



The company has entered a purchase and sale agreement concerning non-operated oil and natural gas interests in one of the most prolific jurisdictions of hydrocarbon potential, Oklahoma&rsquo;s SCOOP/STACK. Based on this acquisition, <a href="https://seekingalpha.com/article/4668347-evolution-petroleum-corporation-epm-q2-2024-earnings-call-transcript">current production</a> can generate approximately 1,550 barrels of oil equivalent per day (BOE). Lastly, the deal encompasses 21 Ducs, for which the sellers shall bear the completion cost, and 300 more locations, offering great potential for the company. 



Financially, the company has demonstrated strong performance. It <a href="https://seekingalpha.com/article/4668347-evolution-petroleum-corporation-epm-q2-2024-earnings-call-transcript">reporting revenue</a> of $21.0 million and net income of $1.1 million, or $0.03 per diluted share for the current quarter. Clearly, this showcases EPM&rsquo;s operational efficiency and financial discipline. These results are underpinned by a <a href="https://seekingalpha.com/pr/19615241-evolution-petroleum-reports-second-quarter-fiscal-2024-results-and-declares-quarterly-cash?hasComeFromMpArticle=false">robust Adjusted EBITDA</a> of $6.8 million for the quarter and $13.5 million for the first half of fiscal 2024. This is a major highlight for Evolution Petroleum&rsquo;s operational efficiency and financial discipline.



Finally, the company&rsquo;s solid foundation allows this development to be a new growth strategy based on strong financial groundwork. In fact, the low-debt profile has always been the company&rsquo;s proud statement and will remain so. Typically, the company enters an acquisition to be debt-free in one year. Therefore, this financial prudence with a robust balance sheet has allowed the company to pursue opportunities for additional growth.



<h2>Organon (OGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/womens-health-300x169.jpg" alt="Pink pills form the shape of the Venus symbol on a light wooden background."><div>Source: Shutterstock</div></div>Organon (NYSE:<a href="https://investorplace.com/stock-quotes/ogn-stock-quote/">OGN</a>) delivers solid top-line growth and nominal and constant currency, supporting the company&rsquo;s valuations. For instance, in Q4 2023, an&nbsp;<a href="https://s27.q4cdn.com/703211477/files/doc_financials/2023/q4/OGN-Q4-and-FY-2023-Press-Release.pdf">8%&nbsp;increase YOY</a> was consistent across all five geographies and three franchisees. For 2023, the top line stood at $6.3 billion, exceeding the high end of the revenue guidance range. Despite adversities like the impact of COVID-19 and the loss of exclusivity (LOE) for certain products, Organon attained 3% top-line growth at constant currency. 



Focusing on the Women&rsquo;s Health Franchise, the women&rsquo;s health <a href="https://s27.q4cdn.com/703211477/files/doc_financials/2023/q4/02/Transcript-Organon-Co-Q4-2023-Earnings-Call-Feb-15-2024.pdf">franchise delivered&nbsp;3% growth</a>&nbsp;for 2023. Contributors to this growth included fertility products like Jada and Marvelon. Together, these products offset the LOE impact of NuvaRing and other headwinds. OGN yielded a solid 9% growth globally in 2023, with considerable contributions from the U.S. and Chinese markets. Nexplanon, despite facing adversities, attained market lead in the long-acting reversible contraceptive market in the U.S., surpassing the best-selling intrauterine device.



Furthermore, Jada contributed $43 million to the top line in 2023, with plans for further expansion into international markets in 2024. Similarly, Marvelon and Mercilon <a href="https://s27.q4cdn.com/703211477/files/doc_financials/2023/q4/02/Transcript-Organon-Co-Q4-2023-Earnings-Call-Feb-15-2024.pdf">grew by&nbsp;24%&nbsp;in 2023</a>, driven by the reacquisition of rights in selected territories in Asia. Moreover, there is an introduction to Xaciato, a Food and Drug Administration-approved medication for bacterial vaginosis. This further diversified the women&rsquo;s health portfolio and marked Organon&rsquo;s entry into new therapeutic areas.



On the other hand, the biosimilars business yielded growth of 24% for the year, based on products like Renflexis and Hadlima. Renflexis attained its sixth consecutive year of top-line growth, primarily in the U.S. and Canadian markets. Hence, these product developments may continue to boost Organon&rsquo;s rapid valuation expansion potential.



As of this writing, Yiannis Zourmpanos held a long position in HSII. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines.</a>
<div>Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT793994">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793989">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793998">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/02/under-the-radar-3-overlooked-stocks-ready-to-dominate-the-market/">Under the Radar: 3 Overlooked Stocks Ready to Dominate the Market</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Under the Radar: 3 Overlooked Stocks Ready to Dominate the Market

Organon & Co. (OGN) has disclosed a new risk, in the Taxation & Government Incentives category. Organon & Co. anticipates that the global shift in ...

Organon & Co. Is Worried About This – Should You Be Worried Too?

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biomea Fusion (BMEA – Research Report), Gritstone On...

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Gritstone Oncology (GRTS) and Organon (OGN)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
As March begins, the stock market promises a high playground to turn modest investments into massive wealth. Amidst this enthusiasm, three top stock picks for rally stand out as pillars of opportunity. Behind each ticker lies an iceberg of strategic progression and market leads with the potential for high returns.



Learn what these top stock picks for rally mean and their potential to maximize gains. Read more to delve into these companies&rsquo; fundamentals, progress and strategic directions and strategies behind the opportunities they present for financial prosperity.



<h2>Despegar (DESP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/travel-stocks-1600-300x169.jpg" alt="A photo of an excited woman riding on the back of a bike a man is driving."><div>Source: OPOLJA / Shutterstock.com</div></div>Despegar&rsquo;s (NYSE:<a href="https://investorplace.com/stock-quotes/desp-stock-quote/">DESP</a>) top-line, aggressive bookings and B2C focus support its valuation expansion. For instance, in Q3 2023, Despegar attained a record top-line of top-line million. This represents a considerable boost of 22% year-over-year (YOY). This growth is special as it outpaces industry averages and reflects the edge of the company&rsquo;s commercial execution and solid demand in core markets (such as Brazil and Mexico).



Additionally, the company substantially increased gross bookings, hitting $1.4 billion in Q3, marking a 25% YOY growth. This surge in gross bookings highlights Despegar&rsquo;s capability to attract customers and generate sales across its various travel offerings. This also indicates strong market leads and progressive execution of growth strategies.



At the bottom-line, Despegar reported a remarkable 106% YOY increase in adjusted EBITDA, reaching $24.7 million in Q3 2023. This improvement in profitability underscores the company&rsquo;s focus on operational efficiency and cost management, leading to enhanced earnings power and shareholder returns. The significant growth in adjusted EBITDA reflects Despegar&rsquo;s ability to leverage its revenue growth and drive operational leverage.



At its core, the B2C channel accounts for&nbsp;<a href="https://s202.q4cdn.com/565082690/files/doc_financials/2023/q3/Despegar-com-Corp-Q3-2023-Earnings-Call-Nov-09-2023.pdf" target="_blank">approximately 85%</a>&nbsp;of Despegar&rsquo;s gross bookings, indicating its strategic importance in driving direct consumer sales and revenue generation. In Q3 2023, the B2C channel contributed significantly to the company&rsquo;s record-breaking gross bookings, reflecting strong consumer demand and effective marketing strategies targeting end-users.



Furthermore, Despegar&rsquo;s B2B and B2B2C channels collectively&nbsp;<a href="https://s202.q4cdn.com/565082690/files/doc_financials/2023/q3/Despegar-com-Corp-Q3-2023-Earnings-Call-Nov-09-2023.pdf" target="_blank">contributed 15%</a>&nbsp;of gross bookings in Q3 2023, highlighting the company&rsquo;s efforts to tap into the offline market and provide technology solutions to business partners. Finally, while currently representing a smaller portion of gross bookings compared to the B2C channel, these segments demonstrate considerable growth potential, especially considering their twofold growth rate compared to B2C.



<h2>Conagra (CAG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/conagra_cag_stock_cag1600-300x169.jpg" alt="Conagra logo on a sign outside of a corporate campus"><div>Source: Jonathan Weiss / Shutterstock.com</div></div>Conagra (NYSE:<a href="https://investorplace.com/stock-quotes/cag-stock-quote/">CAG</a>) executes vital strategic investments that may continue to support its value growth. For instance, Conagra Brands&rsquo; investments in business segments were vital in driving growth and market share gains during Q2 fiscal 2024. The company strategically invested in its frozen business, resulting in substantial lifts and market share gains. Notably, investments in the frozen business led to outstanding responsiveness, with volume trends improving significantly YOY.



During Q2, Conagra deployed high-quality merchandising nationally. This can be observed in its largest frozen business segment, single-serve meals. The results were very encouraging, with&nbsp;<a href="https://www.conagrabrands.com/news-room/news-conagra-brands-reports-second-quarter-results-prn-122874" target="_blank">lifts up to 60%,</a> ultimately driving meaningful gains in market share. Conagra&rsquo;s Q2 share in the single-serve meals business approached 51%, eclipsing last year&rsquo;s gains and setting a new record. This suggests the edge of Conagra&rsquo;s strategic investments in driving consumer engagement and market share growth.



Additionally, Conagra Brands delivered a solid performance in its international and food service segments. The international segment attained organic net sales&nbsp;<a target="_blank" href="https://finance.yahoo.com/news/conagra-brands-inc-nyse-cag-132403974.html">growth of 5.6%</a>&nbsp;during Q2, based on solid performance in key markets such as Mexico. On an organic net sales basis, price/mix increased by 2.3%, and volume increased by 3.3%, primarily based on a solid performance in the company&rsquo;s Mexico business.&nbsp;



Organic net sales in the food service segment&nbsp;increased by 4.3%&nbsp;to $295 million during the quarter. Price/mix increased by 6.8%, primarily due to inflation-driven pricing actions taken in the prior year. While volume decreased by 2.5%, adjusted operating profit increased by 24.3% to $35 million, driven by higher organic net sales, productivity and lower cost of goods sold inflation.



Overall, these trends suggest Conagra&rsquo;s leadership in executing its international growth strategy and capitalizing on demand in emerging markets.



<h2>Organon (OGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/pharmaceutical1600-300x169.png" alt="pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory. Top Stock Picks for Rally"><div>Source: Dmitry Kalinovsky / Shutterstock.com</div></div>Organon&rsquo;s (NYSE:<a href="https://investorplace.com/stock-quotes/ogn-stock-quote/">OGN</a>) consolidated performance growth and stability point out its high valuation potential very precisely. For instance, 2023 revenue stood at&nbsp;<a href="https://s27.q4cdn.com/703211477/files/doc_financials/2023/q4/OGN-Q4-and-FY-2023-Press-Release.pdf" target="_blank">$6.3 billion</a>, marking a 1% increase as reported and a 3% increase at constant currency. Interestingly, the women&rsquo;s health franchise grew by 3%. Similarly, the biosimilar franchise delivered solid growth of 24%.



Fundamentally, the diversified revenue growth across various franchises signifies the stability and resilience of Organon&rsquo;s revenue streams. Despite challenges like loss of exclusivity (LOE) for certain products, revenue growth was achieved through volume expansion and strategic initiatives. Revenue stability was maintained through constant performance across geographies, with China&rsquo;s business demonstrating notable endurance despite economic slowdowns.



At the bottom line, adjusted EBITDA for 2023 was&nbsp;<a href="https://s27.q4cdn.com/703211477/files/doc_financials/2023/q4/02/Transcript-Organon-Co-Q4-2023-Earnings-Call-Feb-15-2024.pdf" target="_blank">$1.9 billion</a>, with an impressive adjusted EBITDA margin of 31.0%. As a result, adjusted diluted EPS for the same period was $4.14. The company targets maintaining or improving adjusted EBITDA margins, with a guided range of 31.0% to 33.0% for 2024. Thus, Organon&rsquo;s solid adjusted EBITDA margin indicates efficient cost management and operational effectiveness, contributing to overall profitability. 



Despite revenue growth, the company has demonstrated control over expenses, leading to margin expansion and enhanced financial performance. Similarly, the guided range for adjusted EBITDA margin in 2024 reflects Organon&rsquo;s focus on sustaining the bottom line while accommodating potential growth initiatives and market shifts.



Looking forward, Organon aims to generate&nbsp;<a href="https://s27.q4cdn.com/703211477/files/doc_financials/2023/q4/02/Transcript-Organon-Co-Q4-2023-Earnings-Call-Feb-15-2024.pdf" target="_blank">$1 billion&nbsp;</a>of free cash flow before one-time charges in 2024. Finally, the net leverage ratio improved to 4.1 times the net leverage in 2023. Organon&rsquo;s robust cash flow generation suggests its strength and stability, providing financial flexibility for strategic initiatives. Overall, improvement in the net leverage ratio indicates progress towards attaining targets and boosting the balance sheet&rsquo;s solidity.



As of this writing, Yiannis Zourmpanos held a long position in CAG. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT793994">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793989">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793998">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/turn-500-into-a-fortune-3-top-stock-picks-for-marchs-million-dollar-rally/">Turn $500 into a Fortune: 3 Top Stock Picks for March&#8217;s Million-Dollar Rally</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Turn $500 into a Fortune: 3 Top Stock Picks for March's Million-Dollar Rally

Teva upgraded at J.P. Morgan on upcoming catalysts

AbbVie keeps Humira market share near 100% despite biosimilars: report

CVS favors Humira copycats hurting AbbVie's market share: Evercore

Chris Shibutani, an analyst from Goldman Sachs, maintained the Hold rating on Organon (OGN – Research Report). The associated price target remains ...

Organon's Steady Market Position Maintains Neutral Rating Amidst Conservative Revenue Forecasts

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Organon (OGN – Research Report), with a price target of $26.00. ...

Barclays Sticks to Their Buy Rating for Organon (OGN)

The Sound Shore Fund Q1 2024 Letter To Shareholders

ABBV

ALVO

AMPH

BMEA

CHRS

DESP

FLEX

FSNUF

FSNUY

GRTS

HSII

NVSEF

PCAR

PCRX

PRGO

RADCQ

RPRX

SDZNY

SDZXF

TEVA

TEVJF

VTRS

Press Releases

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference

Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook

Organon's XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023

Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary

On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Indivior

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly and Co

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)